News & Updates

Show Multimedia Only

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

2 hours ago

Age, rehabilitation timing factor in functional outcomes in stroke survivors

18 hours ago by

Older age and early initiation of rehabilitation predict functional improvement in patients undergoing stroke rehabilitation within Singapore’s community hospital setting, according to local research.

Age, rehabilitation timing factor in functional outcomes in stroke survivors

18 hours ago

CAD incidence lower in HCM vs non-HCM patients

21 hours ago

Patients with hypertrophic cardiomyopathy (HCM) undergoing computed tomography angiography (CTA) for table chest pain enjoy a lower incidence of obstructive coronary artery disease (CAD) and show more stable coronary plaque features than those with no HCM, reveals a study.

CAD incidence lower in HCM vs non-HCM patients

21 hours ago

Delayed puberty in males a red flag for T2D risk

a day ago

Male teens with delayed puberty have an increased likelihood of developing type 2 diabetes (T2D) in early adulthood, regardless of BMI, according to a retrospective study.

Delayed puberty in males a red flag for T2D risk

a day ago

GLP-1RA bests aspirin for CRC prevention

a day ago by

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to confer greater protection against the development of colorectal cancer (CRC) as compared with aspirin, according to a retrospective study.

GLP-1RA bests aspirin for CRC prevention

a day ago

High PUFA slightly better than high MUFA diets in lowering blood lipids

a day ago

Diets high in polyunsaturated fatty acid (PUFA) demonstrate slightly greater benefits over high monounsaturated fatty acid (MUFA) diets in reducing blood lipids, reports a study.

High PUFA slightly better than high MUFA diets in lowering blood lipids

a day ago

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

a day ago by

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

a day ago

Delays in hypertension diagnosis persist despite records of high BP measurement

a day ago

A recent study has observed delays in hypertension diagnosis, which potentially results in hospital visits and other cardiovascular diagnoses.

Delays in hypertension diagnosis persist despite records of high BP measurement

a day ago

Incentivized stepped-care approach cuts diabetes conversion risk in prediabetics

a day ago by

Findings from the Pre-DICTED* trial show that a stepped-care programme, which integrates lifestyle modifications, adds metformin as needed, and provides financial incentives, effectively reduces the risk of diabetes conversion in patients with prediabetes in Singapore.

Incentivized stepped-care approach cuts diabetes conversion risk in prediabetics

a day ago

$Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma$

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

06 Feb 2026

In the treatment of patients with relapsed or refractory follicular lymphoma, adding tafasitamab to lenalidomide and rituximab appears to improve progression-free survival (PFS) while having an acceptable safety profile, according to the phase III inMIND study.

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

06 Feb 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

Age, rehabilitation timing factor in functional outcomes in stroke survivors

Age, rehabilitation timing factor in functional outcomes in stroke survivors

CAD incidence lower in HCM vs non-HCM patients

CAD incidence lower in HCM vs non-HCM patients

Delayed puberty in males a red flag for T2D risk

Delayed puberty in males a red flag for T2D risk

GLP-1RA bests aspirin for CRC prevention

GLP-1RA bests aspirin for CRC prevention

High PUFA slightly better than high MUFA diets in lowering blood lipids

High PUFA slightly better than high MUFA diets in lowering blood lipids

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Delays in hypertension diagnosis persist despite records of high BP measurement

Delays in hypertension diagnosis persist despite records of high BP measurement

Incentivized stepped-care approach cuts diabetes conversion risk in prediabetics

Incentivized stepped-care approach cuts diabetes conversion risk in prediabetics

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma

Add-on tafasitamab prolongs PFS in relapsed, refractory follicular lymphoma